{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-034976","form_type":"8-K","ticker":"BVS","cik":"0001665988","company_name":"Bioventus Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.029748+00:00","generated_at":"2026-05-31T12:19:14.461225+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Bioventus Q2 revenue up 10.3% (organic +13.9%); raises FY2024 guidance","bullets":["Revenue $151.2M (+10.3% YoY); Pain Treatments +17.2%, Surgical Solutions +18.6% US.","Net loss from continuing operations $32.1M vs $4.7M, including $31.9M impairment and litigation settlement.","Adjusted EBITDA $34.5M (+22.4% YoY); non-GAAP EPS $0.19 vs $0.14.","Raising FY2024 guidance: revenue $557-567M, adjusted EBITDA $104-107M, non-GAAP EPS $0.36-0.42.","FDA clearance for OSTEOAMP Cannula; pursuing divestiture of Advanced Rehabilitation to reduce debt."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-034976","json":"https://secwatch.observer/filing/0001628280-24-034976.json","markdown":"https://secwatch.observer/filing/0001628280-24-034976.md","text":"https://secwatch.observer/filing/0001628280-24-034976.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000162828024034976/0001628280-24-034976-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000162828024034976/bvs-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:19:14.461225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}